Back

Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex and hypertension in patients with T2DM and high CV risk: EMPA-reg outcome.

29 August 2017 (16:39 - 16:48)
Organised by:
Congress Presentation Part of: Optimising cardiovascular pharmacotherapy Drug therapy ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Odd Erik Johansen

Nestle Health Science, Hovik (Norway)

7 More presentations in this session

Presentation thumbnail
Beneficial effect of beta-blockers on clinical outcomes persist after discontinuation in patients with ST elevation myocardial infarction?
Assistant Professor J. Park (Suwon, KR)
Abstract Slides Video
Presentation thumbnail
Monocyte chemoattractant protein-1 level and (-75)G/A polymorphism of APOA1 gene predict response and resistance to intensive statin therapy in very high cardiovascular risk patients.
Professor S. Villevalde (Saint Petersburg, RU)
Abstract Slides Video
Presentation thumbnail
Efficacy of evinacumab in homozygous familial hypercholesterolemia patients with null or non-null LDL-receptor mutations and on various background therapies
Doctor G. Hovingh (Amsterdam, NL)
Abstract
Presentation thumbnail
Riociguat ameliorates right ventricular function in patients with pulmonary hypertension.
Assistant Professor M. Murata (Kanagawa, JP)
Abstract Slides Video
Presentation thumbnail
The beneficial effects of renin angiotensin system blockades on two years outcomes in coronary artery ectasia patients
Doctor Y. Wang (Beijing, CN)
Abstract

Access the full session

Session thumbnail
Optimising cardiovascular pharmacotherapy

The Event

Event poster

ESC Congress 2017

29 August 2017 16:39 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources